ATLAS (Antimicrobial Testing Leadership and Surveillance) Program
Conducted by Pfizer
Active: 2004 Onwards
Countries: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Cameroon, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Egypt, El Salvador, Estonia, Finland, France, Germany, Ghana, Greece, Guatemala, Honduras, Hong Kong, Hungary, India, Indonesia, Ireland, Israel, Italy, Ivory Coast, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malawi, Malaysia, Mauritius, Mexico, Morocco, Namibia, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, Uganda, Ukraine, United Kingdom, United States, Venezuela, Vietnam
Primary objective
The ATLAS programme monitors changes in antibiotic susceptibility, bacterial resistance trends and emergence of new resistance mechanism for both marketed and in development antibiotics. In addition, provides genotypic information when tested. The SENTRY platform data allow for monitoring of antifungal susceptibility and resistance trending of key antifungals.
| Protocol Summary | The ATLAS program is one overall study (formerly TEST, INFORM and AWARE) fulfilling regulatory requirements and supporting appropriate use measures for both marketed antibiotics (Tygacil, Zyvox, Zosyn/Tazocin, Zavicefta, Zinforo, Merrem and others) by monitoring changes in antibiotic susceptibility, bacterial resistance trends and emergence of new resistance mechanisms. CLSI breakpoints are utilized but the option exists to analyse the data by using EUCAST breakpoints. All bacterial isolate identifications and susceptibility profiles are performed by standardized broth microdilution methods by a central lab. The antifungal data from the SENTRY platform are generated by standardized antifungal susceptibility methods performed at a central laboratory. |
| Isolates collection method: | Actively collected from local labs and sent to central laboratory for identification and susceptibility testing. |
| Types of surveillance: | Isolates are collected specifically for surveillance. |
| Methodology and breakpoints: | CLSI breakpoints are utilized but the option exists to analyse the data by using EUCAST breakpoints. |
| Number of Isolates | 858,233 |
| Contains pediatric data? | Yes |
| Contains genotype data? | Yes |
| Date Last Updated | December 2021 |
| Expected frequency of updates to the dataset | Annually |
| List of publications to be linked | Can be found at www.atlas-surveillance.com on the resources tab. Published poster with some details on the protocol: www.ihma.com/app/uploads/Pfizer_P107_ATLAS-Overview_IDWeek-2020_FINAL.pdf |
| Any additional information | The ATLAS database is updated every 9 to 12 months with emerging data from across 83 countries. Data for compounds in development are not made available via the public website but are available via publications and medical requests for information. Year in and year out integrated, with search by individual year possible as well. Database system built by Micron Research, UK. |